Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.142561 | 1 | 1 |
Echinococcus granulosus | mitogen activated protein kinase | 0.142561 | 1 | 1 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.142561 | 1 | 1 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.142561 | 1 | 1 |
Giardia lamblia | Kinase, CMGC MAPK | 0.142561 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.142561 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.142561 | 1 | 1 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.142561 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.142561 | 1 | 1 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.142561 | 1 | 1 |
Plasmodium falciparum | protein kinase 5 | 0.0185334 | 0 | 0.5 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.142561 | 1 | 1 |
Plasmodium vivax | protein kinase Crk2 | 0.0185334 | 0 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.142561 | 1 | 1 |
Brugia malayi | MAP kinase sur-1 | 0.142561 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.142561 | 1 | 1 |
Entamoeba histolytica | cell division protein kinase 2, putative | 0.0185334 | 0 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.142561 | 1 | 1 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.142561 | 1 | 1 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.142561 | 1 | 1 |
Entamoeba histolytica | cell division protein kinase 2, putative | 0.0185334 | 0 | 0.5 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.142561 | 1 | 1 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.142561 | 1 | 1 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.142561 | 1 | 1 |
Trypanosoma brucei | protein kinase, putative | 0.142561 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -4.038 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.016 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the P388 Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -3.915 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -3.693 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -3.672 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -3.602 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -3.602 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -3.602 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -3.602 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (functional) | = 3 uM | Antiprotozoal activity against erythrocytic stages chloroquine- and pyrimethamine-resistant Plasmodium falciparum K1 assessed as inhibition of [3H]hypoxanthine incorporation pre-incubated for 48 hrs prior [3H]hypoxanthine addition measured after 24 hrs by liquid scintillation counting | ChEMBL. | 22285027 |
IC50 (functional) | = 31 uM | Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes after 72 hrs by alamar blue assay | ChEMBL. | 22285027 |
IC50 (functional) | = 170 uM | Antiprotozoal activity against Trypanosoma cruzi Tulahuen C2C4 amastigotes infected in rat L6 myoblasts after 96 hrs by CPRG/Nonidet-based spectrophotometry | ChEMBL. | 22285027 |
IC50 (functional) | = 270 uM | Antiprotozoal activity against Leishmania donovani MHOM/ET/67/L82 axenic amastigotes after 72 hrs by alamar blue assay | ChEMBL. | 22285027 |
MIC (functional) | > 350 uM | Antituberculosis activity against Mycobacterium tuberculosis H37Rv after 7 to 14 days by twofold serial broth dilution method | ChEMBL. | 22285027 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | 22285027 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.